NeuroIQ: AI-Driven Coagulation Monitoring for Multimorbidity in ECMO Patients

Entity Overview
BrainHeart Therapeutics, a woman-led healthcare innovator based in Málaga’s Technology Park, Spain, specializes in AI-driven medical devices for critical care and oncology. Our mission is to enhance patient outcomes through precision diagnostics and real-time monitoring, positioning us as a leader in Andalusia’s health ecosystem. With a proven track record of the founders of this venture in CDTI/Eureka/Horizon-funded projects and experience with the EU MDR system two FDA Breakthrough Designations and several US FDA approval, we deliver cutting-edge solutions for unmet clinical needs.

Project Overview: NeuroIQ Coagulation Monitoring System
The NeuroIQ Coagulation Monitoring System is an AI-enabled microfluidic device for real-time blood/gas analysis (pO₂, pCO₂, coagulation) in ECMO patients, addressing multimorbidity (e.g., obesity, pulmonary/cardiac issues, 2-10% stroke risk). At TRL 4-5, it automates non-invasive sampling and predictive clotting models, reducing ICU complications by 30%. This aligns with EP PerMed’s RITC2026 call for multimodal data solutions, testing in hospital environments to support personalized medicine for chronic disease management.

R&D Activities

• Product: Develop a scalable NeuroIQ platform integrating multimodal data (blood, physiological signals) for decision support (e.g., anticoagulant dosage) and remote monitoring.

• Activities: Enhance AI/ML for blood/gas analysis, validate in real-world hospital settings, develop secure big data platforms.

• BrainHeart (Spain, SME, Lead, ): Lead medical device development and sensor - microrobotics adaptation, Spanish hospital validation, biomarker integration.

• Expected Partner Contributions: Develop big data/AI prediction algorithms, co-validate in clinical trials, support manufacturing/regulatory pathways.

Consortium

• BrainHeart Therapeutics (Spain, SME, ): Leads microfluidic-AI integration, funded via Spain & Andalucia.

• We are in discussion with academic partners in both Spain and Sweden, the goal is creating a consortium with partners in three countries

Technical Expectations from Partner

• Expertise in AI/ML for multimodal health data (blood/gas analysis, predictive algorithms).

• Facilities for big data platforms, clinical datasets, or microfluidic manufacturing.

• Experience in real-world validation or regulatory compliance (e.g., CE marking).

Commercial Expectations and Market Opportunity
NeuroIQ targets the €155 billion European medtech market and $10 billion point-of-care diagnostics market by 2032, with applications in critical care (ECMO, stroke detection) and oncology (biomarker extensions). Partners will co-develop market-ready solutions, securing joint IP and regulatory approvals (e.g., CE marking, MFDS) for EU and global expansion. ECMO’s multimorbidity (obesity, cardiac/pulmonary, stroke) ensures high-impact adoption in hospitals, reducing costs ($1M/patient in ICU complications) and improving outcomes.

Funding and Timeline

• Total Budget: €1.6M (3 years, Q1 2026 – Q2 2029).

• Funding: CDTI (Spain, 70% for SMEs), Vinnova (Sweden, 100% for academia), TÜBİTAK (Türkiye), self-funding for Brazil.

• Deadline: Pre-proposal January 12, 2026; full proposal April 27, 2026.

Contact
Julia Waleij, CEO, BrainHeart Therapeutics
Email: julia@scandic-medical.com
Website: www.brainheart.es
Partner in building a consortium via PT-Outline (ptoutline.eu) or the RITC2026 Matchmaking Event (November 18, 2025, b2match.com).